Health committee  One of the values in our new strategic plan is transparency. That's driving a lot of change within the organization. One of the things we're working hard to implement is to reduce the number of redactions in the reports that are made public. The public will see more and more of w

Health committee  I would add that the regulatory review of drugs and devices, R2D2, is actually including the use of foreign reviews as one of the projects. Again, Health Canada is the best organization to speak to that, but from what we hear from the regulators, they're already beginning to dete

Health committee  I'll offer a comment to start. One of the key elements that I think will be absolutely necessary to have in place, and that currently needs some infrastructure support and coordination, is around real-world evidence. If you imagine a future state where we can conditionally appro

Health committee  There are pockets of excellence around the world. There are components of the process that work exceedingly well in some jurisdictions. If any jurisdiction had this mapped out perfectly, I think we would be one of the first organizations to try to copy that jurisdiction as much a

Health committee  Both pCODR and CDR have targets. In general, it takes between six and nine months. It depends on the complexity of the file, and whether there are specific requirements to go back to the manufacturer for clarification.

Health committee  We need to continue to advance the collaborative nature of the partnerships between Health Canada, INESSS, PMPRB and pCPA. We need to be willing to be innovative and try new things. This aligned review...I think you heard from the people who presented from Health Canada. It reall

Health committee  Each of our expert panels has a deliberative framework that tells the committee how to consider its review process in making funding recommendations. Cost-effectiveness and clinical impact are central to that discussion. In fact, cost-effectiveness is an assessment that equalizes

Health committee  I would respond in two ways. There is more alignment across the drug review and approval system now than perhaps at any point in history. We do work very closely with pCPA, with PMPRB, with the provinces, with Health Canada and INESSS. I would say it's better than it's ever been.

Health committee  In my presentation, I specifically articulated some of those challenges. Drugs for highly complex, specialized, ultra-rare and rare diseases are often plagued by a number of problems. They have insufficient evidence, so we have limited confidence in the ability of that drug to ha

Health committee  No, access to information requests are possible through the provinces, which are members of CADTH. To the best of my knowledge, there's no ability for access to information requests through CADTH.

Health committee  I'm not sure that I can answer that question.

Health committee  Most of our budget comes from the federal government, but there is a mechanism to access those, to provide those funds by the provinces. The majority of the funding comes through the federal government. It isn't the only source of funding. We also have a small amount of funding t

Health committee  There certainly are opportunities to review CADTH's work and make sure that we're aligning with the needs of our customers. Most recently, as an example, there was a review of all eight federally funded pan-Canadian health organizations and CADTH was part of that. There were dis

Health committee  Our customers are the deputy ministers of health, but our board includes some deputy ministers, some assistant deputy ministers and some researchers, ethicists and clinicians, so it isn't just deputy ministers of health. Some of the assistant deputy ministers who are on our board

Health committee  That is correct. I would just clarify that the recommendations that come through either CDEC, which is the CDR expert review committee, or pERC, which is the pCODR expert review committee, are entirely independent of the board of directors. They're entirely independent of the cl